Tarceva approved for smokers, updates labeling on hepatic failure
Executive Summary
OSI/Genentech's Tarceva (erlotinib) is now indicated for non-small cell lung cancer patients who currently smoke cigarettes, following a Sept. 19 approval. FDA reports that "the submitted data, together with previous findings, indicate that smoking reduces erlotinib exposure in both cancer patients and healthy volunteers." The agency notes that the optimal dose adjustment to compensate for this alteration is not known. Labeling is also updated Sept. 23 after cases of hepatic failure and hepatorenal syndrome, including fatalities, were reported. New data are added from a pharmacokinetic study in patients with moderate hepatic impairment associated with significant liver tumor burden, along with statements in Warnings and Dosage and Administration sections
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.